Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

ReachMD Healthcare Image



Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing hemodialysis will be presented in a poster at the National Kidney Foundation Spring Clinical Meetings 2022 (SCM22), to be held April 6-10, 2022, in Boston, MA.

Details for the poster presentation are as follows:

Title: Reduction of Pruritus by Difelikefalin Correlates With Reductions in Markers for Pruritus and Inflammation in Subjects Undergoing Hemodialysis
Poster Number: 207
Date and Time: April 7, 2022, 6:00-7:30 p.m. ET
Presenter: Shayan Shirazian, MD, Columbia University College of Physicians and Surgeons, New York, NY

In addition, details for other posters highlighting KORSUVA injection are as follows:

Title: Effect of Treatment with Difelikefalin on Itch Severity in Patients with Chronic Kidney Disease-Associated Pruritus Measured by the Patient Global Impression of Change
Poster Number: 212

Title: Improvement in Itch-Related Sleep Disruption with Difelikefalin in Patients with Moderate to Severe Chronic Kidney Disease Associated Pruritus Undergoing Hemodialysis: A Post-hoc Analysis of an Open-Label, Multicenter Study
Poster Number: 261

Title: CKD-associated Pruritus After 12 Weeks of Therapy with Difelikefalin Among Hemodialysis Patients with Severe Pruritus: A Post-hoc Analysis of Phase 3 Studies
Poster Number: 262

Facebook Comments


We’re glad to see you’re enjoying Eye Health Academy…
but how about a more personalized experience?

Register for free